The investigators' overall objective is to assess the effectiveness, implementation and costs of a streamlined TB diagnostic evaluation strategy based around rapid, onsite molecular testing. The intervention strategy was developed based on theory-informed assessment of barriers to TB diagnostic evaluation at community health centers in Uganda and a process of engagement with local stakeholders. It includes: 1) Point-of-care molecular testing using GeneXpert as a replacement for sputum smear microscopy; 2) Re-structuring of clinic-level procedures to facilitate same-day TB diagnosis and treatment; and 3) Quarterly feedback of TB evaluation metrics to health center staff. The investigators' central hypothesis is that the intervention strategy will have high uptake and increase the number of patients diagnosed with and treated for active pulmonary TB. To test this hypothesis, the investigators will conduct a pragmatic cluster-randomized trial at community health centers that provide TB microscopy services in Uganda in partnership with the National TB Program (NTP). The investigators utilize an effectiveness-implementation hybrid design in which, concurrent with the clinical trial, the investigators will conduct nested mixed methods, health economic and modeling studies to assess 1) whether the intervention strategy modifies targeted barriers to TB diagnostic evaluation; 2) fidelity of implementation of the intervention components (i.e, the degree to which intervention components were implemented as intended vs. adapted across sites); and 3) cost-effectiveness and public health impact.
Aim 1: To compare patient outcomes at health centers randomized to intervention vs. standard-of-care TB diagnostic evaluation strategies. The investigators will randomize 20 community health centers to continue standard TB evaluation (routine microscopy plus referral of patients for Xpert testing per existing processes of care) or to implement the intervention strategy (1. Onsite molecular testing; 2. Re-structuring clinic-level procedures to facilitate same-day TB diagnosis and treatment; and 3. Performance feedback). The investigators will compare reach and effectiveness based on the numbers and proportions of patients (N=5500) who complete TB testing, are found to have TB, and have treatment initiated within one week of specimen provision. Aim 2: To identify processes and contextual factors that influence the effectiveness and fidelity of the intervention TB diagnostic evaluation strategy. The investigators will use quantitative process metrics to assess the adoption and maintenance over time of the core components of the intervention strategy. The investigators will also collect quantitative and qualitative data to describe the fidelity of implementation of each component and faithfulness to the conceptual model. Aim 3: To compare the costs and epidemiological impact of intervention vs. standard-of-care TB diagnostic evaluation strategies. The investigators will model the incremental costs and cost-effectiveness of intervention relative to standard-of-care TB diagnostic evaluation from the health system and patient perspective. The investigators will then construct an epidemic model of the population-level impact of the intervention strategy on TB incidence and mortality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
10,644
Onsite molecular testing with GeneXpert I as a replacement for microscopy
Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
Feedback of TB diagnostic evaluation quality indicators to health center staff
St Francis Njeru Health Center III
Buikwe, Uganda
Busana Health Center III
Busana, Uganda
Busesa Health Center IV
Busesa, Uganda
Buwama Health Center III
Buwama, Uganda
Iganga TC
Iganga, Uganda
Bukulula Health Center IV
Kalungu, Uganda
Nazigo Health Center III
Kayunga, Uganda
Kiganda Health Center IV
Kiganda, Uganda
Kira Health Center III
Kira, Uganda
Lugasa Health Center III
Lugala, Uganda
...and 10 more locations
Number Treated for Microbiologically-confirmed TB Within 14 Days After Presentation to the Health Center for TB Evaluation
Effectiveness outcome.
Time frame: Within 14 days after presentation to the health center for tuberculosis evaluation
Number Diagnosed With Microbiologically-confirmed TB
Effectiveness outcome.
Time frame: Within 14 days after presentation to the health center for tuberculosis evaluation
Time to Microbiologically-confirmed TB
Effectiveness outcome. Time-to-diagnosis if microbiologically-confirmed TB.
Time frame: Within 6 months of presentation to the health center for tuberculosis evaluation
Number Treated for TB
Effectiveness outcome.
Time frame: Within 14 days of presentation to the health center for tuberculosis evaluation
Time-to-treatment of Microbiologically-confirmed TB
Effectiveness outcome. Time-to-treatment if microbiologically-confirmed TB and treated.
Time frame: Days from initial health center visit to initiation of treatment if diagnosed, up to 6 months.
Number Who Died Within 6 Months
Effectiveness outcome.
Time frame: Within 6 months of presentation to the health center for tuberculosis evaluation
Number of Patients Enrolled
Effectiveness outcome.
Time frame: Presentation to the health center for tuberculosis evaluation during the 16-month study time frame
Number Tested for TB According to National Guidelines
Effectiveness outcome.
Time frame: Within 6 months of presentation to the health center for tuberculosis evaluation
Number Suspected/Diagnosed With Rifampin-resistant TB
Effectiveness outcome.
Time frame: Within 6 months of presentation to the health center for tuberculosis evaluation
Number Diagnosed and Treated for Microbiologically-confirmed TB
Effectiveness outcome.
Time frame: On the same-day of presentation to the health center for tuberculosis evaluation
Number Diagnosed AND Treated for TB
Effectiveness outcome.
Time frame: On the same-day of presentation to the health center for tuberculosis evaluation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.